Glucosio Fresenius Kabi Italia (Glucose Monohydrate)

Glucosio Fresenius Kabi Italia is indicated for several clinical situations where rapid glucose supplementation or fluid replacement is required.

• Treatment of hypoglycemia when oral glucose is not feasible.
• Provision of an energy source in parenteral nutrition regimens.
• Fluid replacement in patients with dehydration or electrolyte imbalance.
• Support of plasma glucose levels during surgery or critical illness.
• Dilution medium for compatible intravenous medications.

Adverse reactions to Glucosio Fresenius Kabi Italia are generally related to the intravenous administration of a glucose solution.

Common

• Transient hyperglycemia, especially in patients with impaired glucose tolerance.
• Local irritation or pain at the infusion site.
• Mild electrolyte shifts such as decreased serum potassium.
• Nausea or vomiting following rapid infusion.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Volume overload causing pulmonary edema in susceptible individuals.
• Hyperosmolar hyperglycemic state in diabetic patients.

Before using Glucosio Fresenius Kabi Italia, clinicians should evaluate patient-specific factors and monitor relevant parameters.

• Assess blood glucose levels and adjust infusion rate to avoid hyperglycemia.
• Use caution in patients with renal or cardiac failure due to risk of fluid overload.
• Verify compatibility with other intravenous solutions; avoid mixing with calcium‑containing fluids.
• Monitor electrolytes, particularly potassium and sodium, during prolonged administration.
• Contraindicated in individuals with known hypersensitivity to glucose monohydrate or formulation excipients.
• Consider reduced infusion rates in neonates and pediatric patients.
• Ensure aseptic technique to prevent catheter‑related infections.

Glucosio Fresenius Kabi Italia may interact with other intravenously administered agents, influencing glucose metabolism or solution compatibility.

Avoid

• Concurrent infusion of high‑concentration dextrose solutions that could cause hyperosmolarity.
• Co‑administration with insulin bolus doses without appropriate glucose monitoring.
• Mixing with calcium or phosphate solutions that may precipitate.

Use with caution

• Simultaneous use of diuretics that affect electrolyte balance.
• Administration alongside beta‑adrenergic agonists, which can raise blood glucose.
• Concurrent parenteral nutrition containing other carbohydrate sources.
• Use with vasopressors that may alter peripheral perfusion and infusion site tolerance.